PTC Therapeutics (NASDAQ:PTCT) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut shares of PTC Therapeutics (NASDAQ:PTCT) from a buy rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Several other research analysts have also recently issued reports on the stock. Zacks Research cut shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Truist Financial started coverage on PTC Therapeutics in a report on Friday, October 16th. They set a “hold” rating and a $62.00 target price on the stock. Barclays upped their target price on PTC Therapeutics from $120.00 to $122.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Raymond James Financial set a $106.00 price target on PTC Therapeutics in a research report on Tuesday, October 20th. Finally, TD Cowen boosted their price objective on PTC Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, PTC Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $95.64.

PTC Therapeutics Trading Down 7.0%

PTCT opened at $59.97 on Friday. The business’s 50 day moving average is $65.36 and its 200-day moving average is $70.78. The stock has a market cap of $5.01 billion, a PE ratio of -42.84, a price-to-earnings-growth ratio of 1.81 and a beta of 0.49. PTC Therapeutics has a twelve month low of $58.80 and a twelve month high of $90.87.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.76). The business had revenue of $357.81 million during the quarter, compared to analysts’ expectations of $306.43 million. PTC Therapeutics’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.20 earnings per share. As a group, analysts forecast that PTC Therapeutics will post 1.19 EPS for the current year.

Insider Buying and Selling

In other PTC Therapeutics news, CEO Matthew Klein sold 10,292 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $68.57, for a total transaction of $705,722.44. Following the completion of the sale, the chief executive officer directly owned 383,868 shares of the company’s stock, valued at approximately $26,321,828.76. This represents a 2.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Mark Boulding sold 2,813 shares of PTC Therapeutics stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $72.57, for a total transaction of $204,139.41. Following the completion of the transaction, the vice president directly owned 105,272 shares in the company, valued at approximately $7,639,589.04. This trade represents a 2.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 77,370 shares of company stock worth $5,322,261. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in PTC Therapeutics during the third quarter valued at about $276,000. Profund Advisors LLC boosted its stake in shares of PTC Therapeutics by 56.2% during the 3rd quarter. Profund Advisors LLC now owns 35,877 shares of the biopharmaceutical company’s stock worth $2,324,000 after acquiring an additional 12,904 shares in the last quarter. Vise Technologies Inc. boosted its stake in shares of PTC Therapeutics by 3.1% during the 3rd quarter. Vise Technologies Inc. now owns 8,826 shares of the biopharmaceutical company’s stock worth $572,000 after acquiring an additional 266 shares in the last quarter. State of Wyoming increased its holdings in shares of PTC Therapeutics by 15.3% during the 3rd quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 260 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of PTC Therapeutics by 15.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,228 shares of the biopharmaceutical company’s stock valued at $989,000 after acquiring an additional 2,027 shares during the last quarter.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
• Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
• Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
• Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.